Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Regeneron's issues in the past ...

The Eylea franchise -- including a high-dose (HD) formulation that first earned ... Regeneron and Sanofi are also seeking a label expansion for Dupixent in treating a rare skin disease called ...

EVP Marion McCourt responded that EYLEA HD's profile, including durability and potential label enhancements, strengthens its competitive position. Tyler Van Buren, TD Cowen: Asked about the timing ...

For EYLEA HD, label expansions and a prefilled syringe are expected to drive uptake. Libtayo is targeting new approvals in skin and lung cancers. Dupixent is expanding into COPD, chronic urticaria ...

So with once all of those enhancements are on the label, we think EYLEA HD will be positioned to have all the indications that they're looking for as well as the highest level of dosing flexibility.

For EYLEA HD, label expansions and a prefilled syringe are expected to drive uptake. Libtayo is targeting new approvals in skin and lung cancers. Dupixent is expanding into COPD, chronic urticaria ...

In the fourth quarter, Eylea HD accounted for just 20% of combined ... which it shares with Sanofi-- is doing great. Fresh off a label expansion in treating COPD last year, the medicine is the ...